Literature DB >> 21802369

Neuropathologically defined subtypes of Alzheimer's disease with distinct clinical characteristics: a retrospective study.

Melissa E Murray1, Neill R Graff-Radford, Owen A Ross, Ronald C Petersen, Ranjan Duara, Dennis W Dickson.   

Abstract

BACKGROUND: Neurofibrillary pathology has a stereotypical progression in Alzheimer's disease (AD) that is encapsulated in the Braak staging scheme; however, some AD cases are atypical and do not fit into this scheme. We aimed to compare clinical and neuropathological features between typical and atypical AD cases.
METHODS: AD cases with a Braak neurofibrillary tangle stage of more than IV were identified from a brain bank database. By use of thioflavin-S fluorescence microscopy, we assessed the density and the distribution of neurofibrillary tangles in three cortical regions and two hippocampal sectors. These data were used to construct an algorithm to classify AD cases into typical, hippocampal sparing, or limbic predominant. Classified cases were then compared for clinical, demographic, pathological, and genetic characteristics. An independent cohort of AD cases was assessed to validate findings from the initial cohort.
FINDINGS: 889 cases of AD, 398 men and 491 women with age at death of 37-103 years, were classified with the algorithm as hippocampal sparing (97 cases [11%]), typical (665 [75%]), or limbic predominant (127 [14%]). By comparison with typical AD, neurofibrillary tangle counts per 0.125 mm(2) in hippocampal sparing cases were higher in cortical areas (median 13, IQR 11-16) and lower in the hippocampus (7.5, 5.2-9.5), whereas counts in limbic-predominant cases were lower in cortical areas (4.3, 3.0-5.7) and higher in the hippocampus (27, 22-35). Hippocampal sparing cases had less hippocampal atrophy than did typical and limbic-predominant cases. Patients with hippocampal sparing AD were younger at death (mean 72 years [SD 10]) and a higher proportion of them were men (61 [63%]), whereas those with limbic-predominant AD were older (mean 86 years [SD 6]) and a higher proportion of them were women (87 [69%]). Microtubule-associated protein tau (MAPT) H1H1 genotype was more common in limbic-predominant AD (54 [70%]) than in hippocampal sparing AD (24 [46%]; p=0.011), but did not differ significantly between limbic-predominant and typical AD (204 [59%]; p=0.11). Apolipoprotein E (APOE) ɛ4 allele status differed between AD subtypes only when data were stratified by age at onset. Clinical presentation, age at onset, disease duration, and rate of cognitive decline differed between the AD subtypes. These findings were confirmed in a validation cohort of 113 patients with AD.
INTERPRETATION: These data support the hypothesis that AD has distinct clinicopathological subtypes. Hippocampal sparing and limbic-predominant AD subtypes might account for about 25% of cases, and hence should be considered when designing clinical, genetic, biomarker, and treatment studies in patients with AD. FUNDING: US National Institutes of Health via Mayo Alzheimer's Disease Research Center, Mayo Clinic Study on Aging, Florida Alzheimer's Disease Research Center, and Einstein Aging Study; and State of Florida Alzheimer's Disease Initiative.
Copyright © 2011 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21802369      PMCID: PMC3175379          DOI: 10.1016/S1474-4422(11)70156-9

Source DB:  PubMed          Journal:  Lancet Neurol        ISSN: 1474-4422            Impact factor:   44.182


  42 in total

1.  Incidence of cerebrovascular lesions in Alzheimer's disease: a postmortem study.

Authors:  Kurt A Jellinger; Johannes Attems
Journal:  Acta Neuropathol       Date:  2002-10-22       Impact factor: 17.088

2.  Relative frequencies of Alzheimer disease, Lewy body, vascular and frontotemporal dementia, and hippocampal sclerosis in the State of Florida Brain Bank.

Authors:  Warren W Barker; Cheryl A Luis; Alice Kashuba; Mercy Luis; Dylan G Harwood; David Loewenstein; Carol Waters; Pat Jimison; Eugene Shepherd; Steven Sevush; Neil Graff-Radford; Douglas Newland; Murray Todd; Bayard Miller; Michael Gold; Kenneth Heilman; Leilani Doty; Ira Goodman; Bruce Robinson; Gary Pearl; Dennis Dickson; Ranjan Duara
Journal:  Alzheimer Dis Assoc Disord       Date:  2002 Oct-Dec       Impact factor: 2.703

3.  Neuron loss from the hippocampus of Alzheimer's disease exceeds extracellular neurofibrillary tangle formation.

Authors:  Jillian J Kril; Smita Patel; Antony J Harding; Glenda M Halliday
Journal:  Acta Neuropathol       Date:  2001-12-12       Impact factor: 17.088

4.  Serial MRI and CSF biomarkers in normal aging, MCI, and AD.

Authors:  P Vemuri; H J Wiste; S D Weigand; D S Knopman; J Q Trojanowski; L M Shaw; M A Bernstein; P S Aisen; M Weiner; R C Petersen; C R Jack
Journal:  Neurology       Date:  2010-07-13       Impact factor: 9.910

5.  Evolution from pretangle neurons to neurofibrillary tangles monitored by thiazin red combined with Gallyas method and double immunofluorescence.

Authors:  T Uchihara; A Nakamura; M Yamazaki; O Mori
Journal:  Acta Neuropathol       Date:  2001-06       Impact factor: 17.088

6.  Hippocampal sclerosis in advanced age: clinical and pathological features.

Authors:  Peter T Nelson; Frederick A Schmitt; Yushun Lin; Erin L Abner; Gregory A Jicha; Ela Patel; Paula C Thomason; Janna H Neltner; Charles D Smith; Karen S Santacruz; Joshua A Sonnen; Leonard W Poon; Marla Gearing; Robert C Green; John L Woodard; Linda J Van Eldik; Richard J Kryscio
Journal:  Brain       Date:  2011-05       Impact factor: 13.501

7.  Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade.

Authors:  Clifford R Jack; David S Knopman; William J Jagust; Leslie M Shaw; Paul S Aisen; Michael W Weiner; Ronald C Petersen; John Q Trojanowski
Journal:  Lancet Neurol       Date:  2010-01       Impact factor: 44.182

8.  Argyrophilic grain disease is a sporadic 4-repeat tauopathy.

Authors:  Takashi Togo; Naruhiko Sahara; Shu-Hui Yen; Natalie Cookson; Takashi Ishizawa; Mike Hutton; Rohan de Silva; Andrew Lees; Dennis W Dickson
Journal:  J Neuropathol Exp Neurol       Date:  2002-06       Impact factor: 3.685

9.  Temporoparietal atrophy: a marker of AD pathology independent of clinical diagnosis.

Authors:  Jennifer L Whitwell; Clifford R Jack; Scott A Przybelski; Joseph E Parisi; Matthew L Senjem; Bradley F Boeve; David S Knopman; Ronald C Petersen; Dennis W Dickson; Keith A Josephs
Journal:  Neurobiol Aging       Date:  2009-11-14       Impact factor: 4.673

10.  Early-onset versus late-onset Alzheimer's disease: the case of the missing APOE ɛ4 allele.

Authors:  Wiesje M van der Flier; Yolande Al Pijnenburg; Nick C Fox; Philip Scheltens
Journal:  Lancet Neurol       Date:  2010-12-22       Impact factor: 44.182

View more
  333 in total

1.  Alzheimer disease: AD pathology--emerging subtypes or age-of-onset spectrum?

Authors:  Eliezer Masliah; Lawrence A Hansen
Journal:  Nat Rev Neurol       Date:  2011-12-06       Impact factor: 42.937

2.  Accuracy of the clinical diagnosis of Alzheimer disease at National Institute on Aging Alzheimer Disease Centers, 2005-2010.

Authors:  Thomas G Beach; Sarah E Monsell; Leslie E Phillips; Walter Kukull
Journal:  J Neuropathol Exp Neurol       Date:  2012-04       Impact factor: 3.685

3.  Simulated brain biopsy for diagnosing neurodegeneration using autopsy-confirmed cases.

Authors:  Sriram Venneti; John L Robinson; Subhojit Roy; Matthew T White; Jennifer Baccon; Sharon X Xie; John Q Trojanowski
Journal:  Acta Neuropathol       Date:  2011-09-30       Impact factor: 17.088

4.  The Road Ahead to Cure Alzheimer's Disease: Development of Biological Markers and Neuroimaging Methods for Prevention Trials Across all Stages and Target Populations.

Authors:  E Cavedo; S Lista; Z Khachaturian; P Aisen; P Amouyel; K Herholz; C R Jack; R Sperling; J Cummings; K Blennow; S O'Bryant; G B Frisoni; A Khachaturian; M Kivipelto; W Klunk; K Broich; S Andrieu; M Thiebaut de Schotten; J-F Mangin; A A Lammertsma; K Johnson; S Teipel; A Drzezga; A Bokde; O Colliot; H Bakardjian; H Zetterberg; B Dubois; B Vellas; L S Schneider; H Hampel
Journal:  J Prev Alzheimers Dis       Date:  2014-12

5.  The power of neuroimaging biomarkers for screening frontotemporal dementia.

Authors:  Corey T McMillan; Brian B Avants; Philip Cook; Lyle Ungar; John Q Trojanowski; Murray Grossman
Journal:  Hum Brain Mapp       Date:  2014-03-31       Impact factor: 5.038

6.  Effects of APOE promoter polymorphism on the topological organization of brain structural connectome in nondemented elderly.

Authors:  Ni Shu; Xin Li; Chao Ma; Junying Zhang; Kewei Chen; Ying Liang; Yaojing Chen; Zhanjun Zhang
Journal:  Hum Brain Mapp       Date:  2015-08-28       Impact factor: 5.038

7.  Dissociating Statistically-Determined Alzheimer's Disease/Vascular Dementia Neuropsychological Syndromes Using White and Gray Neuroradiological Parameters.

Authors:  Catherine C Price; Jared J Tanner; Ilona M Schmalfuss; Babette Brumback; Kenneth M Heilman; David J Libon
Journal:  J Alzheimers Dis       Date:  2015       Impact factor: 4.472

8.  Yes/no versus forced-choice recognition memory in mild cognitive impairment and Alzheimer's disease: patterns of impairment and associations with dementia severity.

Authors:  Lindsay R Clark; Nikki H Stricker; David J Libon; Lisa Delano-Wood; David P Salmon; Dean C Delis; Mark W Bondi
Journal:  Clin Neuropsychol       Date:  2012-10-02       Impact factor: 3.535

Review 9.  Challenges of multimorbidity of the aging brain: a critical update.

Authors:  Kurt A Jellinger; Johannes Attems
Journal:  J Neural Transm (Vienna)       Date:  2014-08-05       Impact factor: 3.575

10.  Alzheimer's disease first symptoms are age dependent: Evidence from the NACC dataset.

Authors:  Josephine Barnes; Bradford C Dickerson; Chris Frost; Lize C Jiskoot; David Wolk; Wiesje M van der Flier
Journal:  Alzheimers Dement       Date:  2015-04-24       Impact factor: 21.566

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.